Biopharmaceutical Study of Glyco pMDI With or Without Charcoal Block vs IV Bolus in Healthy Volunteers

NCT01176851 | Completed Phase 1

• 1 other identifier: CCD-0915-PR-0031
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to investigate the pharmacokinetics, the absolute bioavailability and the lung bioavailability of inhaled Glyco pMDI.

Conditions

Healthy

Keywords

None (study in healthy volunteers)

Outcome Measures

Primary Outcomes (1)

• Plasma and urine pharmacokinetics of glycopyrrolate

  over 24 h post dose

Secondary Outcomes (4)

• Lung function parameters

  over 24 h post dose

• Cardiovascular parameters

  over 24 h post dose

• Clinical chemistry and haematology, urinalysis

  over 24 h post dose

• Adverse Events

  during the whole study period

Study Arms (3)

Glyco pMDI

EXPERIMENTAL

Glyco pMDI 100 µg

Drug: Glycopyrrolate

Glyco pMDI Charcoal

EXPERIMENTAL

Glyco pMDI 100 µg + charcoal block

Drug: Glycopyrrolate

Glyco IV injection

ACTIVE COMPARATOR

Glyco solution for injection 100 µg

Drug: Glycopyrrolate

Interventions

Glycopyrrolate DRUG

Single administration of Glyco pMDI 100 µg

Also known as: CHF 5259

Glyco pMDI

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Males and females healthy volunteers aged 18-65 years;
• Written informed consent obtained before the first trial related activity.
• Able to understand the study procedures, the risks involved and ability to be trained to use the devices correctly.
• Body Mass Index (BMI) between 18.0 and 32.0 kg/m2;
• Non- or ex-smokers who smoked \< 5 pack years;
• Good physical and mental status;
• Normal blood pressure and heart rate;
• Electrocardiogram (ECG)considered as normal;
• Results of laboratory tests within the normal ranges.
• Lung function measurements within the normal ranges.

You may not qualify if:

• Blood donation (equal or more than 450 ml) or blood loss less than 8 weeks before inhalation of the study medication;
• Pregnant or lactating women or women of childbearing potential, UNLESS they are using one or more of the acceptable methods of contraception. Male subjects not willing to use an acceptable method of contraception.
• Positive HIV1 or HIV2 serology;
• Positive results from the Hepatitis serology which indicates acute or chronic Hepatitis B or Hepatitis C;
• Unsuitable veins for repeated venipuncture;
• History of substance abuse or drug abuse within 12 months prior to screening visit or with a positive urine drug screen at screening;
• Clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical investigation;
• Clinically significant and uncontrolled cardiac, hepatic, renal, gastrointestinal, endocrine, metabolic, neurologic, or psychiatric disorder that may interfere with successful completion of this protocol;
• Participation in another clinical trial less than 8 weeks prior to inhalation of the study medication; participation in another clinical trial using radioactive material within 1 calendar year;
• History of hypersensitivity to M3 Antagonists or any of the excipients contained in any of the formulations used in the trial;
• Any drug treatment, including prescribed or OTC medicines as well as vitamins, homeopathic remedies etc, taken in the 14 days (2 months for enzyme-inducing or enzyme-inhibiting drugs e.g., glucocorticoids, phenobarbital, isoniazid) preceding the first intake of the study drug, with the exception of occasional paracetamol (maximum 2 g per day with a maximum of 10 g per 14 days for mild non-excluding conditions).
• Treatment within the previous 3 months with any drug known to have a well defined potential for hepatotoxicity (e.g. isoniazide, nimesulide, ketoconazole).
• Subjects who refuse to abstain from alcohol or caffeine containing foods or beverages or grapefruit containing foods or beverages from 48 hour prior to the first intake of study medication and for the entire duration of the study.
• Heavy caffeine drinker.

Sponsors & Collaborators

• Chiesi Farmaceutici S.p.A.: lead

Study Sites (1)

Medicines Evaluation Unit

Manchester, M23 9QZ, United Kingdom

Location

Related Links

• CSR Synopsis available in the Chiesi Clinical Study Register

MeSH Terms

Interventions

Glycopyrrolate

Intervention Hierarchy (Ancestors)

Quaternary Ammonium Compounds; Amines; Organic Chemicals; Onium Compounds; Pyrrolidines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Study Officials

• Dave Singh, MD

  Medicines Evaluation Unit

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: August 5, 2010
• First Posted: August 6, 2010
• Study Start: July 1, 2010
• Primary Completion: October 1, 2010
• Study Completion: October 1, 2010
• Last Updated: October 29, 2021

Record last verified: 2021-10

Locations

GB (1)